𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human cytokines, tumor necrosis factor, and interferons: Gene cloning, animal studies, and clinical trials

✍ Scribed by Arthur P. Bollon; Susan L. Berent; Richard M. Torczynski; Norwood O. Hill; Yuri Lemeshev; Joseph M. Hill; Feng Lan Jia; Anwar Joher; Sathit Pichyangkul; Amanullah Khan


Book ID
102880246
Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
865 KB
Volume
36
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Presented is a comprehensive program designed to isolate human cytokine genes and investigate their relative induction, and to analyze cytokine activities in cell culture, animal tumor models, and human clinical trials. Human cytokine cDNAs have been isolated from a cDNA library made from normal human peripheral blood leukocytes (PBLs) treated with Sendai virus and the relative induction of tumor necrosis factor (TNF), alpha and gamma interferons (IFN-a, IFN-y), and interleukin-1 beta IL-1P) genes has been analyzed. In the Sendai virus-induced PBL system, IL-10 mRNA was shown to be approximately twofold higher than TNF or IFN-a mRNA whereas IFN-y mRNA was 50-100-fold lower than TNF or IFN-a mRNA. The cytotoxic activity of TNF was analyzed on several cell lines and IFN-a and IFN-y were shown to potentiate TNF cytotoxicity about 2-200-fold depending on cell lines. The LD50 for recombinant TNF in BALB/c mice was determined to be 6 X lo7 U/kg and the therapeutic dose of recombinant TNF in sarcoma 180 bearing BALB/c mice was 3 X 1 6 U/kg, indicating a wide therapetic index. Phase I clinical trials of recombinant TNF given I.V. indicated a tolerated dose of 150,000 U/kg with biphasic half-life (T-1/2) of 2 and 31 min following TNF injection. Phase II trials of TNF and trials of TNF combined with IFN-a are in progress. These studies indicate that cytokines such as TNF and IFN-a are subject to similar induction systems, potentiate each other's activities, and can be tolerated at specific doses for potential therapeutic use.


πŸ“œ SIMILAR VOLUMES


Interferon-gamma, tumor necrosis factor-
✍ L. Malaguarnera; M. Musumeci; M. Di Rosa; A. Scuto; S. Musumeci πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 125 KB

## Abstract Human chitotriosidase (Chit), a chitinolytic enzyme, is a member of the chitinase family. In human plasma, Chit activity has been proposed as a biochemical marker of macrophage activation in several lysosomal diseases. Recently we found that Chit activity is higher in patients affected

Increased production of interferon gamma
✍ J. Beck; P. Rondot; L. Catinot; E. Falcoff; H. Kirchner; J. Wietzerbin πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 386 KB

We have carried out a longitudinal study of interferon (IFN) and tumor necrosis factor (TNF) using a whole-blood mitogen stimulation assay in 20 multiple sclerosis (MS) patients and in a healthy control group. We set up individual profiles and the results were quite constant for each individual, bot